• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Xencor Inc. (Amendment)

    2/14/24 6:54:44 PM ET
    $XNCR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $XNCR alert in real time by email
    SC 13G/A 1 xncr13ga.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No. 3)

    Xencor, Inc.

    (Name of Issuer)

    Common Stock, par value $0.01

    (Title of Class of Securities)

    98401F105

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [X]       Rule 13d-1(b)

    [X]       Rule 13d-1(c)

    [ ]       Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     1 
    CUSIP No. 98401F105

     

     

    1.Names of Reporting Persons.

    EcoR1 Capital, LLC

     

    2. Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) X

    (b)

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With:
    5. Sole Voting Power -0-
    6. Shared Voting Power 5,282,516
    7. Sole Dispositive Power -0-
    8. Shared Dispositive Power 5,282,516

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 5,282,516

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 8.7%

     

    12.Type of Reporting Person (See Instructions) OO, IA

     

     2 
    CUSIP No. 98401F105

     

     

    1.Names of Reporting Persons.

    Oleg Nodelman

     

    2. Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) X

    (b)

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization United States

     

    Number of
    Shares
    Beneficially
    Owned by
    Each Reporting
    Person With:
    5. Sole Voting Power -0-
    6. Shared Voting Power 5,282,516
    7. Sole Dispositive Power -0-
    8. Shared Dispositive Power 5,282,516

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 5,282,516

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 8.7%

     

    12.Type of Reporting Person (See Instructions) IN, HC

     

     3 
    CUSIP No. 98401F105

     

     

    1.Names of Reporting Persons.

    EcoR1 Capital Fund Qualified, L.P.

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) ______

     

    3. SEC Use Only

     

     

    4.Citizenship or Place of Organization Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power -0-

     

    6. Shared Voting Power 4,981,480
    7. Sole Dispositive Power -0-
    8. Shared Dispositive Power 4,981,480

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 4,981,480

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 8.2%

     

    12.Type of Reporting Person (See Instructions) PN

     

     

     4 
    CUSIP No. 98401F105

     

     

    Item1.
    (a)Name of Issuer

    Xencor, Inc.

     

    (b)Address of Issuer’s Principal Executive Offices

    465 North Halstead Street, Suite 200, Pasadena, CA 91107

    ________________________________________________________________________

    Item2.
    (a)The names of the persons filing this statement are:

    EcoR1 Capital Fund Qualified, L.P. (“Qualified Fund”); EcoR1 Capital, LLC (“EcoR1”) and Oleg Nodelman (“Nodelman”) (collectively, the “Filers”).

     

    Qualified Fund is filing this statement jointly with the other Filers, but not as a member of a group and it expressly disclaims membership in a group. In addition, filing this Schedule 13G on behalf of Qualified Fund should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any of the Stock covered by this Schedule 13G.

     

    Each Filer also disclaims beneficial ownership of the Stock except to the extent of that person’s pecuniary interest therein.

     

     

    (b)The principal business office of the Filers is located at:

    357 Tehama Street #3, San Francisco, CA 94103

     

    (c)For citizenship of Filers, see Item 4 of the cover sheet for each Filer.

     

    (d)This statement relates to the Issuer’s shares of Common Stock, par value $0.01 (the “Stock”).

     

    (e)The CUSIP number of the Issuer is: 98401F105.
     5 
    CUSIP No. 98401F105

     

    Item 3.If this statement is filed pursuant to rule 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)[ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
    (b)[ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c)[ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d)[ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e)[ X ] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E) as to EcoR1.
    (f)[ ] An employee benefit plan or endowment fund in accordance with section 240.13d-1(b)(1)(ii)(F).
    (g)[ X ] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G)
    as to Mr. Nodelman.
    (h)[ ] A savings association as defined in section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
    (i)[ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
    (j)[ ] Group, in accordance with section 240.13d-1(b)(1)(ii)(J).
    Item 4.Ownership.

    See Items 5-9 and 11 of the cover page for each Filer.

    The percentages reported in this Schedule 13G are based on 60,875,198 shares of Common Stock outstanding as of November 1, 2023, as reported in the Issuer’s Form 10-Q filed on November 8, 2023.

    Item 5.Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

    The funds managed by EcoR1, including Qualified Fund, hold the Stock for the benefit of their investors and have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Stock.

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

    Not applicable.

    Item 8.Identification and Classification of Members of the Group.

    EcoR1 is the general partner and investment adviser of investment funds, including Qualified Fund. Mr. Nodelman is the control person of EcoR1.

     

     

    Item 9.Notice of Dissolution of Group.

    Not applicable.

    Item 10.Certification.

    Certification of EcoR1 and Mr. Nodelman:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    Certification of Qualified Fund:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February 14, 2024

     

    EcoR1 CAPITAL, LLC

     

     

    By: /s/ Oleg Nodelman

    Oleg Nodelman, Manager

     

     

     

     

     

    /s/ Oleg Nodelman
    Oleg Nodelman

    EcoR1 CAPITAL FUND QUALIFIED, L.P.

     

    By: EcoR1 Capital, LLC, General Partner

     

     

    By: /s/ Oleg Nodelman

    Oleg Nodelman, Manager

     

     
     6 
    CUSIP No. 98401F105

    EXHIBIT A

    AGREEMENT REGARDING JOINT FILING
    OF STATEMENT ON SCHEDULE 13D OR 13G

    The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D, Schedule 13G or Forms 3, 4 or 5 (and any amendments or supplements thereto) required under section 13(d) or 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, the undersigned hereby constitute and appoint EcoR1 Capital, LLC a Delaware limited liability company, as their true and lawful agent and attorney-in-fact, with full power and authority for and on behalf of the undersigned to prepare or cause to be prepared, sign, file with the SEC and furnish to any other person all certificates, instruments, agreements and documents necessary to comply with section 13(d) and section 16(a) of the Securities Exchange Act of 1934, as amended, in connection with said purchases, and to do and perform every act necessary and proper to be done incident to the exercise of the foregoing power, as fully as the undersigned might or could do if personally present.

    Dated: February 14, 2024

    EcoR1 CAPITAL, LLC

     

     

    By: /s/ Oleg Nodelman

    Oleg Nodelman, Manager

     

     

     

     

     

    /s/ Oleg Nodelman
    Oleg Nodelman

    EcoR1 CAPITAL FUND QUALIFIED, L.P.

     

    By: EcoR1 Capital, LLC, General Partner

     

     

    By: /s/ Oleg Nodelman

    Oleg Nodelman, Manager

     

     
    Get the next $XNCR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $XNCR

    DatePrice TargetRatingAnalyst
    4/21/2025Outperform
    William Blair
    12/12/2024$37.00Overweight
    Wells Fargo
    12/2/2024$20.00 → $30.00Neutral → Overweight
    Piper Sandler
    4/16/2024$56.00 → $38.00Buy
    BTIG Research
    2/28/2024$37.00 → $24.00Overweight → Neutral
    Piper Sandler
    5/19/2023$42.00Buy
    BofA Securities
    12/6/2022Outperform
    Cowen
    10/13/2022$58.00Outperform → Strong Buy
    Raymond James
    More analyst ratings

    $XNCR
    Leadership Updates

    Live Leadership Updates

    See more
    • Xencor Appoints Todd Simpson to Board of Directors

      Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced the appointment of Todd Simpson to its board of directors. Mr. Simpson has more than 40 years of experience in chief financial officer (CFO) roles at multiple biopharmaceutical companies and in public accounting. Most recently he served as CFO at Seagen Inc. through its acquisition in 2023. "Mr. Simpson is an accomplished finance and operations executive with broad experience in corporate strategy, and he played a key role in transforming a small development-stage biotech company into one of the most successful growth c

      3/13/25 4:01:00 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xencor Appoints Bart Cornelissen as Chief Financial Officer

      Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the appointment of Bart Cornelissen to senior vice president and chief financial officer. Mr. Cornelissen has more than 20 years of experience in corporate financial planning, analysis and transaction support. Before joining Xencor, he was most recently vice president, corporate finance at Seagen Inc., where he was instrumental in the company's transformation into a global, multi-product organization that generated over $2 billion in annual revenue. "Bart's exceptional track record in financial planning and analysis

      4/9/24 8:01:00 AM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xencor Appoints Barbara J. Klencke, M.D., to Board of Directors

      Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the appointment of Barbara J. Klencke, M.D., to its board of directors. Dr. Klencke has more than 20 years of biopharmaceutical product development experience, and she most recently served as chief medical officer and chief development officer at Sierra Oncology through mid-2023. While at Sierra Oncology, she built a highly effective clinical development organization and led its strategy and execution, culminating in the approval of Ojjaara™ for myelofibrosis following the company's acquisition by GSK. "D

      9/19/23 4:01:00 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XNCR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Xencor Reports First Quarter 2025 Financial Results

      -- Recent interim Phase 1 study results for XmAb942 (Xtend™ anti-TL1A) support a 12-week maintenance dosing interval in XENITH-UC, a Phase 2b study in participants with ulcerative colitis, to begin in the second half of 2025 -- -- Chief development officer and former independent director, Nancy Valente, M.D., to transition to senior advisory role -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the first quarter ended March 31, 2025 and provided a review of recent business and program updates. "Recently presented interim Phase 1 results suppo

      5/7/25 4:01:00 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease

      -- XENITH-UC, a Phase 2b study of XmAb942 in participants with ulcerative colitis, to begin in the second half of 2025 -- -- Single and multiple doses of XmAb942 are well tolerated and safety profile is consistent with the anti-TL1A drug class -- -- XmAb942 half-life supports a 12-week maintenance dosing interval in XENITH-UC -- -- Lead selection for XmAb TL1A x IL23p19 program on track for first-in-human study start in 2026 -- -- Management hosting webcast and conference call at 5:00 p.m. ET / 2:00 p.m. PT today -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced

      4/29/25 4:01:00 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xencor Appoints Todd Simpson to Board of Directors

      Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced the appointment of Todd Simpson to its board of directors. Mr. Simpson has more than 40 years of experience in chief financial officer (CFO) roles at multiple biopharmaceutical companies and in public accounting. Most recently he served as CFO at Seagen Inc. through its acquisition in 2023. "Mr. Simpson is an accomplished finance and operations executive with broad experience in corporate strategy, and he played a key role in transforming a small development-stage biotech company into one of the most successful growth c

      3/13/25 4:01:00 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XNCR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Gorman Kevin Charles bought $1,013 worth of shares (53 units at $19.12), increasing direct ownership by 1% to 5,060 units (SEC Form 4)

      4 - Xencor Inc (0001326732) (Issuer)

      2/15/24 4:02:46 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XNCR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, Chief Development Officer Valente Nancy sold $50,914 worth of shares (4,616 units at $11.03), decreasing direct ownership by 9% to 49,169 units (SEC Form 4)

      4 - Xencor Inc (0001326732) (Issuer)

      5/6/25 4:40:24 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SR. VICE PRESIDENT & CFO Cornelissen Bart Jan sold $30,233 worth of shares (3,750 units at $8.06), decreasing direct ownership by 6% to 61,348 units (SEC Form 4)

      4 - Xencor Inc (0001326732) (Issuer)

      4/14/25 4:13:39 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Simpson Todd E

      4 - Xencor Inc (0001326732) (Issuer)

      3/13/25 7:03:03 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XNCR
    Financials

    Live finance-specific insights

    See more
    • Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease

      -- XENITH-UC, a Phase 2b study of XmAb942 in participants with ulcerative colitis, to begin in the second half of 2025 -- -- Single and multiple doses of XmAb942 are well tolerated and safety profile is consistent with the anti-TL1A drug class -- -- XmAb942 half-life supports a 12-week maintenance dosing interval in XENITH-UC -- -- Lead selection for XmAb TL1A x IL23p19 program on track for first-in-human study start in 2026 -- -- Management hosting webcast and conference call at 5:00 p.m. ET / 2:00 p.m. PT today -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced

      4/29/25 4:01:00 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs

      – Phase 1 healthy volunteer study of half-life extended anti-TL1A antibody XmAb942 to dose first subject in Q4 2024, with data anticipated in the first half of 2025 – – XmAb® T-cell engagers plamotamab (CD20 x CD3) and XmAb657 (CD19 x CD3) to be evaluated in autoimmune diseases, with respective Phase 1b/2a and Phase 1 studies to initiate in 2025 – – Ongoing Phase 1 dose escalation of XmAb819 (ENPP3 x CD3) in advanced clear cell renal cell carcinoma shows initial encouraging clinical activity including RECIST responses – – Management hosting webcast and conference call at 8:00 a.m. ET / 5:00 a.m. PT today – Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing

      9/9/24 7:31:00 AM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xencor to Host Research & Development Webcast and Conference Call on Monday, September 9, 2024

      Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that management will host a webcast and conference call at 8:00 a.m. ET (5:00 a.m. PT) on Monday, September 9, 2024 to introduce new XmAb® programs in development for the treatment of patients with autoimmune diseases and to provide updates on continued progress in dose escalation with first-in-class oncology programs, including XmAb819 (ENPP3 x CD3) in patients with advanced clear cell renal cell carcinoma and XmAb808 (B7-H3 x CD28) in patients with advanced solid tumors. The live webcast may be accessed through "E

      9/6/24 8:01:00 AM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XNCR
    SEC Filings

    See more
    • SEC Form 10-Q filed by Xencor Inc.

      10-Q - Xencor Inc (0001326732) (Filer)

      5/7/25 4:09:38 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xencor Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits

      8-K - Xencor Inc (0001326732) (Filer)

      5/7/25 4:03:09 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Xencor Inc.

      DEFA14A - Xencor Inc (0001326732) (Filer)

      4/23/25 4:06:50 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XNCR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on Xencor

      William Blair initiated coverage of Xencor with a rating of Outperform

      4/21/25 8:40:03 AM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo initiated coverage on Xencor with a new price target

      Wells Fargo initiated coverage of Xencor with a rating of Overweight and set a new price target of $37.00

      12/12/24 8:18:37 AM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Xencor upgraded by Piper Sandler with a new price target

      Piper Sandler upgraded Xencor from Neutral to Overweight and set a new price target of $30.00 from $20.00 previously

      12/2/24 10:12:11 AM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XNCR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Xencor Inc.

      SC 13G/A - Xencor Inc (0001326732) (Subject)

      11/14/24 6:16:13 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Xencor Inc.

      SC 13G/A - Xencor Inc (0001326732) (Subject)

      11/14/24 1:22:36 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Xencor Inc.

      SC 13G/A - Xencor Inc (0001326732) (Subject)

      11/12/24 4:01:23 PM ET
      $XNCR
      Biotechnology: Pharmaceutical Preparations
      Health Care